Neonatal Seizure. Convulsions of newborn
Conditions
Interventions
Intervention 1: Intervention group 1: Infants receive Lacosamide tablets (manufactured by Dr. Abidi Company, Iran) twice a day at a dosage of 2 mg/kg/day, If no treatment response, 2 mg/kg is added to
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Days to 3 Months
Inclusion criteria
Inclusion criteria: Neonates with seizure who did not respond to phenobarbital (dose40 mg/kg) and Levebel (40 mg/kg). Infants under 3 months with refractory seizures whose seizures have started since infancy (under one month). Seizures due to secondary abnormalities in asphyxia, brain structural disorders, familial seizures, congenital and acquired infections, vascular lesions
Exclusion criteria
Exclusion criteria: Seizures that started after neonatal Period Seizures due to secondary abnormalities in metabolic disorders or electrolyte disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of seizures. Timepoint: Before the intervention, 3 days and 7 days after the intervention. Method of measurement: Electroencephalography (EEG). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Vafaeeshahi
Iran University of Medical Sciences
Outcome results
None listed